Navigation Links
Genome update defines landscape of breast and colon cancers
Date:10/11/2007

One year after completing the first large-scale report sequencing breast and colon cancer genes, Johns Hopkins Kimmel Cancer Center scientists have studied the vast majority of protein-coding genes which now suggest a landscape dominated by genes that each are mutated in relatively few cancers.

Their report, published online in the October 11 issue of Science Express, indicates that while little is known about these less-commonly mutated genes, they can be grouped into clusters according to their pathways.

There are gene mountains represented by those that are frequently altered and have been the focus of cancer research for years, in part because they were the only genes known to contribute to cancer, says Bert Vogelstein, M.D., an investigator at the Howard Hughes Medical Institute and co-director of the Ludwig Center at Johns Hopkins. Now, we can see the whole picture, and it is clear that lower peaks or gene hills are the predominant feature.

In a systematic search of 18,191 genes representing more than 90 percent of the protein-coding genes in the human genome -- about 5,000 more than in the first screen -- the Johns Hopkins scientists found that most cancer-causing gene mutations are quite diverse and can vary from person to person. They found that an average 77 genes are mutated in an individual colon cancer and 81 in breast cancer. Of these, about 15 are likely to contribute to a cancers key characteristics, and most of these genes may be different for each patient.

Fifteen years ago, we said the p53 gene was the most commonly mutated gene in cancer. Its amazing that this is still true, says Kenneth W. Kinzler, Ph.D., professor of oncology at Hopkins Kimmel Cancer Center.

With no more higher-frequency mutations on the horizon, the investigators say that personalized medicines may now focus on the more complicated pathways that link these less-commonly mutated genes.

As an example, the Hopkins
'/>"/>

Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Man and mouse share genome structures
2. Genome of deadly amoeba shows surprising complexity, evidence of lateral gene transfer
3. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
4. Whole genome fine map of rice completed
5. Genome-wide mouse study yields link to human leukemia
6. Study finds more than one-third of human genome regulated by RNA
7. A bacterial genome reveals new targets to combat infectious disease
8. Scientists decipher genome of fungus that can cause life-threatening infections
9. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
10. Highly adaptable genome in gut bacterium key to intestinal health
11. Multiple Campylobacter Genomes Sequenced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)UVALDE Dr. Daniel Leskovar, a Texas AgriLife Research plant physiologist at the Texas AgriLife Research and Extension Center in Uvalde, has been investigating ways to help vegetable plants make a les
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4How to read brain activity? 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 1SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 2SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 3Delawares Partnership to Fight Chronic Disease Breakfast Highlights Promising Practices in Managing Chronic Disease Provides Solutions for Reduced Spe 50419 1Delawares Partnership to Fight Chronic Disease Breakfast Highlights Promising Practices in Managing Chronic Disease Provides Solutions for Reduced Spe 50419 2Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 1Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 2
...archers at MIT recently found an elegant solution ...anics: why water doesn,t soak into soil at an even... fluid flowing downward. , Scientists call these...or their formation has to do with the surface tens... other medium). Knowing how to account for this ph...
...ORD/SOMERVILLE, Mass. -- A new study from the psyc...hen dieters eliminate carbohydrates from their mea...ks than when they reduce calories, but maintain ca... cognition skills returned to normal. , "This stu...immediate impact on cognitive behavior," explains ...
...ANTONIO Douglas Easton, Ph.D., whose internationa...atterns and causes of the BRCA1 and BRCA2 gene mut...ancer, has been selected to receive the inaugural ...tstanding Investigator Award in Breast Cancer Rese... the Cure, recognizes an investigator whose novel ...
Other Biology News:MIT researchers explain mystery of gravity fingers 2Low-carb diets can affect dieters' cognition skills 2Easton honored with inaugural AACR Outstanding Investigator Award in Breast Cancer Research 2
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...ing RNAi Industry through,Addition of Important an...P, PALO ALTO, Calif., April 9, 2008 Intradigm Co...c RNA interference (RNAi),therapeutics, today anno...ty (IP) covering certain efficacy-enhancing struct...m the University of Massachusetts Medical,School. ...
...ronext Brussels: THR), a biotechnology company foc..., announces today that it has completed,patient en...y purpose of,this study is to evaluate the safety ...nistered intravenously to acute stroke patients,be... stroke., MITI IV (Microplasmin in Treatment of I...
...Nasdaq: DNDN ) today announced that it has comple...ering of 8.0 million shares of its common,stock an... its common,stock. Net proceeds received by Dendre...Markets LLC served as sole placement agent for the...o previously effective shelf,registration statemen...
Other Biology Technology:Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 2Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 3Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 4ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 2ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 3Dendreon Announces Closing of Registered Direct Offering 2
Rabbit Anti-Human Rab1A Antibody, Unconjugated from Spring Bioscience
Rat Anti-Acetyl Salicylic Acid conjugated Acetyl Salicylic Acid Polyclonal Antibody, Unconjugated from Cell Sciences
Beadlyte® Human IgE Standard from Upstate
...uct Mouse monoclonal [SPM278] to 67kD Laminin Rec...inoma N592 live cells (Human). Reactivity / Speci... other species. Background Information Laminin, ...e, displays multiple biological activities which a...
Biology Products: